Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puechal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Edwige LM, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sené T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Koné-Paut I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera EM, Kuwana M, Lo Gullo A, Mukuchyan V, Dellal A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Vieira M, Cacoub P, Fain O, Saadoun D; French Takayasu network. Mekinian A, et al. RMD Open. 2023 Jun;9(2):e002830. doi: 10.1136/rmdopen-2022-002830. RMD Open. 2023. PMID: 37321669 Free PMC article.
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.
Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, Fernández-Solà J, Urbano-Márquez A, Grau JM, Cid MC. Hernández-Rodríguez J, et al. Arthritis Rheum. 2002 Feb;47(1):29-35. doi: 10.1002/art1.10161. Arthritis Rheum. 2002. PMID: 11932875 Free article.
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC. Espígol-Frigolé G, et al. Ann Rheum Dis. 2013 Sep 1;72(9):1481-7. doi: 10.1136/annrheumdis-2012-201836. Epub 2012 Sep 19. Ann Rheum Dis. 2013. PMID: 22993227 Clinical Trial.
Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
Alba MA, García-Martínez A, Prieto-González S, Espígol-Frigolé G, Butjosa M, Tavera-Bahillo I, Rodríguez-Pintó I, Hernández-Rodríguez J, Cid MC. Alba MA, et al. Semin Arthritis Rheum. 2014 Jun;43(6):772-7. doi: 10.1016/j.semarthrit.2013.10.009. Epub 2013 Oct 30. Semin Arthritis Rheum. 2014. PMID: 24315461
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy.
Carmona FD, Coit P, Saruhan-Direskeneli G, Hernández-Rodríguez J, Cid MC, Solans R, Castañeda S, Vaglio A, Direskeneli H, Merkel PA, Boiardi L, Salvarani C, González-Gay MA, Martín J, Sawalha AH; Spanish GCA Study Group; Italian GCA Study Group; Turkish Takayasu Study Group; Vasculitis Clinical Research Consortium. Carmona FD, et al. Sci Rep. 2017 Mar 9;7:43953. doi: 10.1038/srep43953. Sci Rep. 2017. PMID: 28277489 Free PMC article.
Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC. Samson M, et al. Eur J Intern Med. 2018 Apr;50:12-19. doi: 10.1016/j.ejim.2017.11.003. Epub 2017 Nov 13. Eur J Intern Med. 2018. PMID: 29146018 Review.
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.
Prieto-González S, Terrades-García N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C, Alba MA, Ponce A, Tavera-Bahillo I, Murgia G, Espígol-Frigolé G, Marco-Hernández J, Hernández-Rodríguez J, García-Martínez A, Unizony SH, Cid MC. Prieto-González S, et al. RMD Open. 2017 Dec 22;3(2):e000570. doi: 10.1136/rmdopen-2017-000570. eCollection 2017. RMD Open. 2017. PMID: 29299342 Free PMC article.
A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility.
González-Serna D, Carmona EG, Ortego-Centeno N, Simeón CP, Solans R, Hernández-Rodríguez J, Tolosa C, Castañeda S, Narváez J, Martinez-Valle F; European GCA Consortium; European Scleroderma Group; Witte T, Neumann T, Holle J, Beretta L, Boiardi L, Emmi G, Cimmino MA, Vaglio A, Herrick AL, Denton CP, Salvarani C, Cid MC, Morgan AW, Fonseca C, González-Gay MA, Martín J, Márquez A. González-Serna D, et al. PLoS One. 2018 Dec 26;13(12):e0209343. doi: 10.1371/journal.pone.0209343. eCollection 2018. PLoS One. 2018. PMID: 30586461 Free PMC article.
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.
Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, Sciascia S, Michaud M, Lambert M, Hernández-Rodríguez J, Schleinitz N, Awisat A, Puéchal X, Aouba A, Munoz Pons H, Smitienko I, Gaultier JB, Le Mouel E, Benhamou Y, Perlat A, Jego P, Goulenok T, Sacre K, Lioger B, Hassold N, Broner J, Dufrost V, Sene T, Seguier J, Maurier F, Berthier S, Belot A, Frikha F, Denis G, Audemard-Verger A, Kone Pault I, Humbert S, Woaye-Hune P, Tomelleri A, Baldissera E, Kuwana M, Lo Gullo A, Gaches F, Zeminsky P, Galli E, Alvarado M, Boiardi L, Muratore F, Vautier M, Campochiaro C, Moiseev S, Cacoub P, Fain O, Saadoun D; French Takayasu network. Mekinian A, et al. Rheumatology (Oxford). 2022 Apr 11;61(4):1376-1384. doi: 10.1093/rheumatology/keab635. Rheumatology (Oxford). 2022. PMID: 34363461
274 results